Document:

EX-10.16

 Exhibit 10.16 

FIFTH AMENDMENT TO CREDIT AGREEMENT 

This Fifth Amendment to Credit Agreement (this “Amendment”) is entered into as of December 9, 2015, by and between WELLS FARGO BANK,
NATIONAL ASSOCIATION (“Bank”) and NIMBLE STORAGE, INC., a Delaware corporation (“Borrower”). 
 RECITALS 

Borrower and Bank are parties to that certain Credit Agreement dated as of October 1, 2013 (as amended from time to time, including by that
certain First Amendment to Credit Agreement dated as of April 23, 2014, that certain Second Amendment to Credit Agreement dated as of June 17, 2014, that certain Third Amendment to Credit Agreement dated as of September 19, 2014 and that certain
Fourth Amendment to Credit Agreement dated as of April 6, 2015, collectively, the “Agreement”). The parties desire to amend the Agreement in accordance with the terms of this Amendment. 

NOW, THEREFORE, the parties agree as follows: 

1. Section 1.1(c) of the Agreement hereby is amended and restated in its entirety to read as follows: 

“(c) Letter of Credit Subfeature. As a subfeature under the Line of Credit, Bank agrees from time to time
during the term thereof to issue or cause an affiliate to issue standby letters of credit for the account of Borrower (each, a “Letter of Credit” and collectively, “Letters of Credit”); provided however, that the aggregate
undrawn amount of all outstanding Letters of Credit (the “Letters of Credit Sublimit”) shall not at any time exceed Seven Million Dollars ($7,000,000). The form and substance of each Letter of Credit shall be subject to approval by Bank,
in its sole discretion. Each Letter of Credit shall be issued for a term not to exceed three hundred sixty five (365) days, as designated by Borrower; provided however, if on the Line of Credit maturity date (or the effective date of any termination
of this Agreement) there are any outstanding Letters of Credit, Borrower shall provide to Bank cash collateral in an amount equal to at least one hundred percent (100%) of the face amount of any such Letter of Credit, plus all interest, fees and
costs due or to become due in connection therewith to secure the obligations related to such Letter of Credit. The undrawn amount of all Letters of Credit shall be reserved under the Line of Credit and shall not be available for borrowings
thereunder. Each Letter of Credit shall be subject to the additional terms and conditions of the Letter of Credit agreements, applications and any related documents required by Bank in connection with the issuance thereof. Each drawing paid under a
Letter of Credit shall be deemed an advance under the Line of Credit and shall be repaid by Borrower in accordance with the terms and conditions of this Agreement applicable to such advances; provided however, that if advances under the Line of
Credit are not available, for any reason, at the time any drawing is paid, then Borrower shall immediately pay to Bank the full amount drawn, together with interest thereon from the date such drawing is paid to the date such amount is fully repaid
by Borrower, at the rate of interest applicable to advances under the Line of Credit. In such event Borrower agrees that Bank, in its sole discretion, may debit any account maintained by Borrower with Bank for the amount of any such drawing.”

 2. The Borrowing Base Certificate incorporated as part of the Loan Documents hereby is replaced with the Borrowing Base Certificate
attached hereto. 
 3. No course of dealing on the part of Bank or its officers, nor any failure or delay in the exercise of any right by
Bank, shall operate as a waiver thereof, and any single or partial exercise of any such right shall not preclude any later exercise of any such right. Bank’s failure at any time to require strict performance by Borrower of any provision shall
not affect any right of Bank thereafter to demand strict compliance and performance. Any suspension or waiver of a right must be in writing signed by an officer of Bank. 

 4. Unless otherwise defined, all initially capitalized terms in this Amendment shall be as
defined in the Agreement. The Agreement, as amended hereby, shall be and remain in full force and effect in accordance with its respective terms and hereby is ratified and confirmed in all respects. Except as expressly set forth herein, the
execution, delivery, and performance of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or remedy of Bank under the Agreement, as in effect prior to the date hereof. 

5. Borrower represents and warrants that the Representations and Warranties contained in the Agreement are true and correct as of the date of
this Amendment, and that no Event of Default has occurred and is continuing. 
 6. As a condition to the effectiveness of this Amendment,
Bank shall have received, in form and substance satisfactory to Bank: 
 (a) this Amendment, duly executed by Borrower; and 

(b) all reasonable fees and expenses incurred through the date of this Amendment, which may be debited from Borrower’s account at Bank.

 7. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one instrument. 
 [Balance of Page Intentionally Left Blank] 

  
 2 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the first date above
written. 
  

			
	NIMBLE STORAGE, INC.

 
			
		
	By:	 	 /s/ Suresh Vasudevan

			
		
	Title:	 	 Chief Executive Officer

			
	
	WELLS FARGO BANK, NATIONAL ASSOCIATION

 
			
		
	By:	 	 /s/ Megan Mix

 
			
		
	Title:	 	 Vice President

 [Signature Page to Fifth Amendment to Credit Agreement] 

			
	 

	 	BBC Exhibit Accounts Receivable Financing

 Collateral Summary and Reconciliation Covering Collateral Activity for Period 

 

											
		 	 From:  
	 	                    	  	To:  	 	                    	  	

 The following is submitted as a reconciliation of the current aging to that of the previous month. 

 

									
	 	  	 	 	 	  	TOTAL	 
	 1.
	  	PREVIOUS ACCOUNTS RECEIVABLE AGING BALANCE:	  	 	$—  	  
	 2.
	  	        ADD: GROSS INVOICES	  	 	$—  	  
		  	        DEDUCT: CREDIT MEMOS	  	 	$—  	  
	 3.
	  	        DEDUCT: CASH RECEIPTS	  	 	$—  	  
		  	        DEDUCT: DISCOUNTS	  	 	$—  	  
	 4.
	  	JOURNAL ENTRIES:	  			
		  	        DEBITS (REFUNDS & OTHER ADJUSTMENTS; DESCRIBE)	  	 	$—  	  
		  	        CREDITS (WRITE OFFS, ETC)	  	 	$—  	  
		  	        OTHER CREDIT ADJUSTMENTS (DESCRIBE)	  	 	$—  	  
	 5.
	  	CONTROL BALANCE (SUM OF LINES 1 THROUGH 4)	  	 	$—  	  
		  		 		  	  
	  
	 
	 6a.
	  	GENERAL LEDGER BALANCE	 	$—  	  			
	 6b.
	  	CURRENT ACCOUNTS RECEIVABLE AGING:	 	$—  	  			
	 7.
	  	LESS: INELIGIBLE RESERVE PER EXHIBIT 1	  	 	$—  	  
	 8.
	  	NET ELIGIBLE ACCOUNTS RECEIVABLE (Line 5 minus Line 7)	  	 	$—  	  
	 9.
	  	MAXIMUM ADVANCE ON ACCOUNTS RECEIVABLE         80%   OF LINE 8	  	 	$—  	  
	 10
	  	MAXIMUM BORROWING BASE (LINE 9 OR CREDIT LINE LIMIT, WHICHEVER IS LOWER)	  	 	$—  	  
		  	        CREDIT LINE LIMIT:	 	$15,000,000	  			
		  	        LESS: STANDBY LC SUBLIMIT:	 	$  7,000,000	  			
		  	        ADJUSTED CREDIT LINE LIMIT:	 	$  8,000,000	  			
			
	 11
	  	LESS: OUTSTANDING LOAN BALANCE AS OF END OF MONTH	  	 	$—  	  
	 12
	  	AVAILABILITY (OVERADVANCE) LINE 10 MINUS LINE 11	  	 	$—  	  

 The above accounts are assigned to Wells Fargo Bank N.A. and security interest granted in accordance with terms and conditions
of the existing continuing security agreement between the undersigned and Wells Fargo Bank N.A. to which reference is made. We hereby certify that the forgoing is true and correct in all particulars and the accounts describe above as collateral
for loans represent accounts which conform to all representations and warranties set forth in said agreement. 
  

							
	 Company Name NIMBLE STORAGE, INC. 
	  		 	Wells Fargo Bank N.A
			
	 Company Address 211 RIVER OAKS PARKWAY 

                   
            SAN JOSE, CA 95134
	  	Received By  	 	  

	 By: Authorized Signature
	 	  
	  		 	
				
	 Title                 
	 	        Date                     	  	        Date                     	 	        Office                     

			
	 

	 	BBC Exhibit Accounts Receivable Financing

  
  

					
	 Exhibit 1 to Borrowing Base Certificate Dated:
	  	 	 
	 Ineligible Accounts Receivable:
	  			
		
	 Past Due From Invoice Date Over 90 Days
	  	$	—  	  
		
	 Credits Over 90 Days
	  	$	—  	  
	 Government
	  	$	—  	  
	 Eligible Foreign Accounts up to 25% of total eligible A/R
	  	$	—  	  
	 Affiliate
	  	$	—  	  
	 Other (Identify)
	  	$	—  	  
	 20% Cross Aged Accounts
	  	$	—  	  
	 Concentrations Over 25% (50% with respect to Avnet, Inc.)
	  	$	—  	  
	 Contra
	  	$	—  	  
		  	  
	  
	 
	 TOTAL INELIGIBLE (Transfer to Line 7 of Certificate)
	  	$	—Exhibit

Exhibit 4.1

January 22, 2016

Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549

RE:  Carnival Corporation, Commission File No. 001-9610, and
        Carnival plc, Commission File No. 001-15136

Ladies and Gentlemen:

Pursuant to Item 601(b) (4) (iii) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended, Carnival Corporation and Carnival plc (the “Companies”) hereby agree to furnish copies of certain long-term debt instruments to the Securities and Exchange Commission upon the request of the Commission and, in accordance with such regulation, such instruments are not being filed as part of the joint Annual Report on Form 10-K of the Companies for their year ended November 30, 2015.

Very truly yours,

CARNIVAL CORPORATION AND CARNIVAL PLC

By:/s/ Arnaldo Perez
Arnaldo Perez
General Counsel and SecretaryExhibit 10.1

 

THIS NOTE AND ANY SHARES ACQUIRED UPON
CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED, SOLD OR
OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER SUCH ACT OR PURSUANT
TO AN OPINION OF COUNSEL SATISFACTORY TO Mount Tam Biotechnologies, Inc. THAT SUCH
REGISTRATION IS NOT REQUIRED.

 

SECURED CONVERTIBLE PROMISSORY NOTE

 

	See Schedule 1 for Principal Amount(s)	Effective Date: November 9, 2015

 

FOR VALUE RECEIVED,
Mount Tam Biotechnologies, Inc., a Nevada corporation (the “Maker”), promises to pay to 0851229 BC Ltd. or its
permitted assigns (the “Holder”) the principal sum of the loans set forth on Schedule 1 hereto (as such
schedule may be updated for future loans), together with interest on the unpaid principal balance(s) under this Note from time
to time outstanding at the rate of 3% per year until paid in full. Subject to the conversion provisions set forth herein, all outstanding
principal and accrued interest shall be due and payable on March 18, 2017. Interest on the outstanding amounts due under this Note
shall be computed for each draw down from the date of each loan (to be set forth on Schedule 1 hereto) on the basis of a
year of 365 days for the actual number of days elapsed. All cash payments by the Maker under this Note shall be in immediately
available funds.

 

As mutually agreed
by the Maker and Holder, Holder may (but is not required to) lend additional funds under this Note, and the Holder and the Maker
shall update Schedule 1 hereto to reflect the dates and amounts of such draw-downs. In the event of any dispute, Holder’s
books and records will be dispositive on the issue of the amounts and dates of the loans absent manifest error.

 

The payment of all
amounts due under this Note, and the performance of all obligations of Maker under this Note, are fully secured by the Security
Agreement between the Maker and Holder effective as of November 9, 2015 (the “Security Agreement”).

 

Effective upon the
closing of any Financing (as defined below) while this Note is outstanding, at the sole and exclusive option of the Holder, some
or all of the outstanding principal and interest under this Note (the “Outstanding Amount”) can be converted
into shares of the same class and series of capital stock of the Maker issued to investors in the Financing (the “Financing
Securities”) at a conversion price equal to 80% of the price per share of Financing Securities paid by the other investors
in the Financing. “Financing” means the issuance of stock by the Maker or any security convertible into, exchangeable
for, or exercisable for stock of the Maker, after the date hereof; provided that the primary purpose of such issuance must be to
raise capital (and as such excludes, for the avoidance of doubt, issuances of stock of the Maker or securities convertible into,
exchangeable for or exercisable for stock of the Maker to employees, directors, consultants or other service providers in connection
with the provision of goods or services to the Maker).

 

     

     

    

 

Effective upon the
closing of any Financing resulting in gross proceeds to the Maker, in one or a series of related transactions, of at least $2,000,000
(including the aggregate amount of any indebtedness converted into equity securities in such Financing) in which either (i) the
investor leading the negotiation with the Maker is a bona fide institutional investor or (ii) if the investor leading the negotiation
is not a bona fide institutional investor, such Financing includes commercially reasonable customary terms and conditions for an
equity financing of an early stage biopharmaceutical company, which may (but shall not be required to) include one or more of the
following terms: liquidation preferences, dividend rights, protective provisions, voting rights, anti-dilution provisions, conversion
rights, board representation for the investors, redemption rights, preemptive rights, information rights, registration rights,
drag-along rights, rights of first refusal and co-sale rights (in the case a Financing satisfies either clause (i) or (ii) above,
a “Qualified Financing”) then the aggregate Outstanding Amount shall automatically without any further action
of the parties be converted into shares of the same class and series of capital stock of the Maker issued to investors in the Qualified
Financing (the “Qualified Financing Securities”) at a conversion price equal to 80% of the price per share of
Qualified Financing Securities paid by the other investors in the Qualified Financing. The parties acknowledge and agree that a
Financing which contains commercially reasonable customary terms and conditions for an equity financing of an early stage biopharmaceutical
company does not have to contain all of the examples of terms listed in sub-clause (ii) of the preceding sentence.

 

The Maker shall notify
the Holder in writing of the anticipated occurrence of a Financing at least 20 days prior to the closing date of the Financing
or any Qualified Financing.

 

In lieu of the Maker
issuing any fractional shares to the Holder upon the conversion of this Note, the Maker shall pay to the Holder an amount equal
to the product obtained by multiplying the applicable conversion price by the fraction of a share not issued pursuant to the conversion
of this Note.

 

Upon the conversion
of this Note pursuant to the terms set forth herein, the Holder agrees to (i) execute and deliver to the Maker a customary 180-day
lock-up agreement in connection with an initial public offering, and (ii) execute and deliver to the Maker all transaction documents
entered into in connection with such conversion, which may include a purchase agreement, investor rights agreement, voting agreement,
right of first refusal and co-sale agreement and/or other ancillary agreements, with customary representations and warranties and
transfer restrictions. The Holder agrees in connection with any conversion of this Note to deliver the original of this Note (or
a notice to the effect that the original Note has been lost, stolen or destroyed and an agreement acceptable to the Maker whereby
the Holder agrees to indemnify the Maker from any loss incurred by it in connection with this Note) prior to conversion.

  

This Note shall become
immediately due and payable without notice or demand (but subject to the conversion rights set forth herein) upon the occurrence
at any time of any of the following events of default (individually, an “Event of Default” and collectively,
“Events of Default”):

 

     

     

    

 

		(1)	the Maker fails to pay any of the principal, interest or any other amounts payable under this Note
when due and payable;

 

		(2)	the Maker files any petition or action for relief under any bankruptcy, reorganization, insolvency
or moratorium law or any other law for the relief of, or relating to, debtors, now or hereafter in effect, or seeks the appointment
of a custodian, receiver, trustee (or other similar official) of the Maker or all or any substantial portion of the Maker’s
assets, or makes any assignment for the benefit of creditors or takes any action in furtherance of any of the foregoing, or fails
to generally pay its debts as they become due;

 

		(3)	an involuntary petition is filed, or any proceeding or case is commenced, against the Maker (unless
such proceeding or case is dismissed or discharged within 60 days of the filing or commencement thereof) under any bankruptcy,
reorganization, arrangement, insolvency, adjustment of debt, liquidation or moratorium statute now or hereafter in effect, or a
custodian, receiver, trustee, assignee for the benefit of creditors (or other similar official) is applied or appointed for the
Maker or to take possession, custody or control of any property of the Maker, or an order for relief is entered against the Maker
in any of the foregoing;

 

		(4)	the occurrence of a breach or default under any agreement, instrument or document to which the
Maker is a party or by which it is bound, involving any obligation for borrowed money of more than $100,000 in the aggregate;

 

		(5)	the Maker materially breaches any other agreement with the Holder (including without limitation
any security agreement); or

 

		(6)	the Maker borrows any funds from a third party without repaying this Note in full (excluding for
this purpose account and trade payables incurred by the Maker in the ordinary course of business), or the Maker is party to a merger,
or there is a sale of a controlling interest in the outstanding stock of the Maker, or a sale of all or substantially all of the
Maker’s assets, or enters into an agreement for any of the foregoing.

 

Upon the occurrence
of an Event of Default, the Holder shall have then, or at any time thereafter, all of the rights and remedies afforded creditors
generally by the applicable federal laws or the laws of the State of California.

 

Notwithstanding anything
to the contrary, this Note may not be prepaid, in whole or in part, without the prior written consent of the Holder. The Maker
shall disclose in writing to the Holder if and when it is in material discussions with respect to a Qualified Financing or a Financing.

 

All payments by the
Maker under this Note shall be made without set-off or counterclaim and be free and clear and without any deduction or withholding
for any taxes or fees of any nature whatever, unless the obligation to make such deduction or withholding is imposed by law.

 

The Maker shall pay
the reasonable costs and expenses (including reasonable attorney’s fees and disbursements) that it incurs and, upon presentation
of appropriate receipts, that the Holder incurs with respect to the preparation, negotiation, execution and delivery of this Note,
any security agreement and any other agreement or instrument contemplated hereby or thereby. After the occurrence of an Event of
Default, the Maker shall pay all costs and expenses, including, without limitation, reasonable attorneys’ fees and court
costs, incurred in connection with any act or actions taken to collect or otherwise satisfy the obligations due under this Note,
any security agreement and any other agreement or instrument contemplated hereby or thereby.

 

     

     

    

 

No delay or omission
on the part of the Holder in exercising any right under this Note shall operate as a waiver of such right or of any other right
of the Holder, nor shall any delay, omission or waiver on any one occasion be deemed a bar to or waiver of the same or any other
right on any future occasion. This Note may not be amended or modified without the prior written consent of the Maker and the Holder.

  

All payments by the
Maker under this Note shall be applied first to any fees and expenses due and payable hereunder, then to the accrued interest due
and payable hereunder and the remainder, if any, to the outstanding principal.

 

The Maker hereby waives
presentment, demand, protest and notices of every kind and assents to any permitted extension of the time of payment and to the
addition or release of any other party primarily or secondarily liable hereunder.

 

Until the conversion
of this Note, the Holder shall not have or exercise any rights by virtue of this Note as a stockholder of the Maker.

 

All rights and obligations
hereunder shall be governed by the laws of the State of California (without giving effect to principles of conflicts or choices
of law) and this Note is executed as an instrument under seal.

 

Neither the Maker nor
the Holder may assign, sell or otherwise transfer this Note or any of their respective rights and duties hereunder without the
prior written consent of the other party hereto.

 

The Maker acknowledges
that neither this Note nor any securities issuable upon the conversion of this this Note (collectively, the “Note Securities”)
will be registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities
laws. The Holder represents that (i) it is acquiring the Note Securities for its own account, for investment purposes only and
not with a view to, or for sale in connection with, any distribution and (ii) it is an “accredited investor” under
Regulation D promulgated under the Securities Act.

 

This Note amends and
restates in their entirety the terms and conditions of the loans made by the Holder to the Maker on November 9, 2015 (the aggregate
principal amount of which was $66,004.25), November 19, 2015 (the aggregate principal amount of which was $25,000), December 17,
2015 (the aggregate principal amount of which is $50,000), January 15, 2016 (the aggregate principal amount of which is $35,000)
and February 2, 2016 (the aggregate principal amount of which was $40,000) (collectively, the “Previous Loans”).
Upon the execution of this Note, (i) the terms and conditions of the Previous Loans shall be automatically without any further
action of the parties be amended and restated to the terms of this Note, (ii) any terms and conditions of the Previous Loans which
conflict with the terms and conditions of this Note shall be of no further force and effect and (iii) each party shall only have
the rights and obligations set forth herein or in the Security Agreement with respect to the Previous Loans. This Note constitutes
the entire contract between the parties hereto with regard to the subject matter hereof. It supersedes any other agreements, representations
or understandings (whether oral or written and whether express or implied) that relate to the subject matter hereof (including
any terms of the Previous Loans).

 

     

     

    

 

IN WITNESS WHEREOF,
the parties have executed this Note effective as of the effective date set forth above.

 

	 	MAKER:
	 	MOUNT TAM BIOTECHNOLOGIES, INC.
	 	 
	 	By: 	/s/ David R. Wells	 
	 	Print Name: David R. Wells
	 	Title: Interim Chief Financial Officer

 

	HOLDER:	 
	0851229 BC Ltd.	 
	 	 
	By: 	/s/ Doug Froese	 	 
	Print Name: Doug Froese	 
	Title: Director	 

 

     

     

    

 

Schedule 1

 

Schedule of Drawdowns 

 

	
        Date
	Amount	Maker Signature
	 	 	 
	11/9/15	$66,004.25	
        /s/ David R. Wells

        Interim Chief Financial Officer

	11/19/15	$25,000	
        /s/ David R. Wells

        Interim Chief Financial Officer

	12/17/15	$50,000	
        /s/ David R. Wells

        Interim Chief Financial Officer

	1/15/16	$35,000	
        /s/ David R. Wells

        Interim Chief Financial Officer

	2/2/16	$40,000	
        /s/ David R. Wells

        Interim Chief Financial Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}]]